Geoffrey Thomas Gibney (Geoffrey T Gibney)

Publication Activity (10 Years)

Years Active: 2022-2023
Publications (10 Years): 8

Top Topics

Advanced Non Small Cell Lung Cancer

Tyrosine Kinase

Clinical Practice

Top Venues

Cancer research communications

Journal for immunotherapy of cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Pamela N Munster, Nicholas O Iannotti, Daniel C Cho, Joanne M Jeter, Liza C Villaruz, Geoffrey Thomas Gibney, Frank Stephen Hodi, Niharika B Mettu, Mark Jones, Jill Bowman, Michael Smith, Mani Lakshminarayanan, Steven J O'Day
Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study. Cancer research communications 3 (12) (2023)
Pamela N Munster, Nicholas O Iannotti, Daniel C Cho, Joanne M Jeter, Liza C Villaruz, Geoffrey Thomas Gibney, Frank Stephen Hodi, Niharika B Mettu, Mark Jones, Jill Bowman, Michael Smith, Mani Lakshminarayanan, Steven J O'Day
Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study. Cancer research communications 3 (12) (2023)
Pamela N Munster, Nicholas O Iannotti, Daniel C Cho, Joanne M Jeter, Liza C Villaruz, Geoffrey Thomas Gibney, Frank Stephen Hodi, Niharika B Mettu, Mark Jones, Jill Bowman, Michael Smith, Mani Lakshminarayanan, Steven J O'Day
Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study. Cancer research communications 3 (12) (2023)
Anna C Pavlick, Charlotte E Ariyan, Elizabeth I Buchbinder, Diwakar Davar, Geoffrey Thomas Gibney, Omid Hamid, Tina J Hieken, Benjamin Izar, Douglas B Johnson, Rajan P Kulkarni, Jason John Luke, Tara C Mitchell, Meghan J Mooradian, Krista M Rubin, April Ks Salama, Keisuke Shirai, Janis M Taube, Hussein A Tawbi, J Keith Tolley, Caressa Valdueza, Sarah A Weiss, Michael K Wong, Ryan J Sullivan
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0. Journal for immunotherapy of cancer 11 (10) (2023)
Pamela N Munster, Nicholas O Iannotti, Daniel C Cho, Joanne M Jeter, Liza C Villaruz, Geoffrey Thomas Gibney, Frank Stephen Hodi, Niharika B Mettu, Mark Jones, Jill Bowman, Michael Smith, Mani Lakshminarayanan, Steven J O'Day
Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study. Cancer research communications 3 (12) (2023)
Gino Kim In, Aparna Nallagangula, Jacob Seung Choi, Lisa Tachiki, Matthew J Blackburn, Stephen Capone, Kathryn B Bollin, Daniel Y Reuben, Keisuke Shirai, Sandy Zhang-Nunes, Omar Ragab, Alicia Terando, Jenny C Hu, Han Lee, Shailender Bhatia, Sunandana Chandra, Jose Lutzky, Geoffrey Thomas Gibney
Clinical activity of PD-1 inhibition in the treatment of locally advanced or metastatic basal cell carcinoma. Journal for immunotherapy of cancer 10 (5) (2022)
Nikhil I Khushalani, Melinda Vassallo, Judith D Goldberg, Zeynep Eroglu, Younchul Kim, Biwei Cao, Robert Ferguson, Kelsey R Monson, Tomas Kirchhoff, Carol M Amato, Paulo Burke, Ann Strange, Emily Monk, Geoffrey Thomas Gibney, Ragini Kudchadkar, Joseph Markowitz, Andrew S Brohl, Anna Pavlick, Alison Richards, David M Woods, Jeffrey S Weber
Phase II clinical and immune correlate study of adjuvant nivolumab plus ipilimumab for high-risk resected melanoma. Journal for immunotherapy of cancer 10 (11) (2022)
Geoffrey Thomas Gibney, Jacob Zaemes, Shelly Shand, Neil J Shah, David Swoboda, Kellie Gardner, Arash Radfar, Vesna Petronic-Rosic, Michael J Reilly, Waddah B Al-Refaie, Suthee Rapisuwon, Michael B Atkins
PET/CT scan and biopsy-driven approach for safe anti-PD-1 therapy discontinuation in patients with advanced melanoma. Journal for immunotherapy of cancer 9 (10) (2022)